Clifford Lane, M.D.
Clinical and Molecular Retrovirology Section
In the laboratory, Dr. Lane’s early work involved studies aimed at dissecting the normal immunoregulatory mechanisms that control the human immune response to specific antigen challenges. When the AIDS epidemic emerged, he became one of the first investigators to study immunopathogenic mechanisms of HIV disease, ultimately making seminal observations that helped establish the field of HIV immunopathogenesis.
Dr. Lane has used investigational therapeutic interventions to further the understanding of HIV pathogenesis. He pioneered the strategies of immunologically compatible bone marrow transplantation and the adoptive transfer of lymphocytes and has examined the roles of cytokines in treating patients with HIV infection.
Dr. Lane received his M.D. from the University of Michigan in 1976. He then completed an internship and residency at the University of Michigan Hospital, Ann Arbor. In 1979, Dr. Lane came to the National Institutes of Health as a clinical associate in the Laboratory of Immunoregulation (LIR). In 1985, he was appointed deputy clinical director of NIAID; in 1989, he became the chief of the Clinical and Molecular Retrovirology Section of LIR, a position he still holds. In 1991, Dr. Lane became clinical director of NIAID and, in 2006, became NIAID Deputy Director for Clinical Research and Special Projects. He is currently on the editorial boards of theJournal of Acquired Immune Deficiency Syndromes and The American Journal of Medicine.
- Imamichi H, Smith M, Adelsberger JW, Izumi T, Scrimieri F, Sherman BT, Rehm CA, Imamichi T, Pau A, Catalfamo M, Fauci AS, Lane HC. Defective HIV-1 proviruses produce viral proteins. Proc Natl Acad Sci U S A. 2020;117(7):3704-3710.
- Di Mascio M, Srinivasula S, Kim I, Duralde G, St Claire A, DeGrange P, St Claire M, Reimann KA, Gabriel EE, Carrasquillo J, Reba RC, Paik C, Lane HC. Total body CD4+ T cell dynamics in treated and untreated SIV infection revealed by in vivo imaging. JCI Insight. 2018;3(13).
- INSIGHT START Study Group., Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015;373(9):795-807.
- Mulangu S, Dodd LE, Davey RT Jr, Tshiani Mbaya O, Proschan M, Mukadi D, Lusakibanza Manzo M, Nzolo D, Tshomba Oloma A, Ibanda A, Ali R, Coulibaly S, Levine AC, Grais R, Diaz J, Lane HC, Muyembe-Tamfum JJ, PALM Writing Group., Sivahera B, Camara M, Kojan R, Walker R, Dighero-Kemp B, Cao H, Mukumbayi P, Mbala-Kingebeni P, Ahuka S, Albert S, Bonnett T, Crozier I, Duvenhage M, Proffitt C, Teitelbaum M, Moench T, Aboulhab J, Barrett K, Cahill K, Cone K, Eckes R, Hensley L, Herpin B, Higgs E, Ledgerwood J, Pierson J, Smolskis M, Sow Y, Tierney J, Sivapalasingam S, Holman W, Gettinger N, Vallée D, Nordwall J, PALM Consortium Study Team.. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. N Engl J Med. 2019;381(24):2293-2303.
- Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC, ACTT-1 Study Group Members.. Remdesivir for the Treatment of Covid-19 - Preliminary Report. N Engl J Med. 2020.
Related Scientific Focus Areas
Microbiology and Infectious Diseases
This page was last updated on Friday, August 21, 2020